These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1319 related articles for article (PubMed ID: 30315511)

  • 1. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.
    Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of Circulatory Metabolites in a Relapsing-remitting Animal Model of Multiple Sclerosis using Global Metabolomics.
    Mangalam A; Poisson L; Nemutlu E; Datta I; Denic A; Dzeja P; Rodriguez M; Rattan R; Giri S
    J Clin Cell Immunol; 2013 Jun; 4():. PubMed ID: 24273690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis.
    Poisson LM; Suhail H; Singh J; Datta I; Denic A; Labuzek K; Hoda MN; Shankar A; Kumar A; Cerghet M; Elias S; Mohney RP; Rodriguez M; Rattan R; Mangalam AK; Giri S
    J Biol Chem; 2015 Dec; 290(52):30697-712. PubMed ID: 26546682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Altered Metabolic Pathways during Disease Progression in EAE Mice via Metabolomics and Lipidomics.
    Lee G; Hasan M; Kwon OS; Jung BH
    Neuroscience; 2019 Sep; 416():74-87. PubMed ID: 31376423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomics approach based on utra-performance liquid chromatography coupled to mass spectrometry with chemometrics methods for high-throughput analysis of metabolite biomarkers to explore the abnormal metabolic pathways associated with myocardial dysfunction.
    Zhao LK; Zhao YB; Yu PC; Zhang PX
    Biomed Chromatogr; 2020 Aug; 34(8):e4847. PubMed ID: 32285481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
    Singh J; Deshpande M; Suhail H; Rattan R; Giri S
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):84-97. PubMed ID: 26277791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of key metabolites during cisplatin-induced acute kidney injury using an HPLC-TOF/MS-based non-targeted urine and kidney metabolomics approach in rats.
    Qu X; Gao H; Sun J; Tao L; Zhang Y; Zhai J; Song Y; Hu T; Li Z
    Toxicology; 2020 Feb; 431():152366. PubMed ID: 31926187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the metabolomics characteristics of patients with metabolic syndrome based on liquid chromatography quadrupole time-of-flight mass spectrometry.
    Wu N; Wang W; Yi M; Cheng S; Wang D
    Ann Endocrinol (Paris); 2018 Feb; 79(1):37-44. PubMed ID: 29246383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease.
    Luan H; Liu LF; Tang Z; Zhang M; Chua KK; Song JX; Mok VC; Li M; Cai Z
    Sci Rep; 2015 Sep; 5():13888. PubMed ID: 26365159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of an Untargeted Metabolomics Approach Using a 2D GC-GC-MS Platform to Distinguish Relapsing and Progressive Multiple Sclerosis.
    Datta I; Zahoor I; Ata N; Rashid F; Cerghet M; Rattan R; Poisson LM; Giri S
    Metabolites; 2024 Sep; 14(9):. PubMed ID: 39330500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of amino acids and acylcarnitines combined with untargeted metabolomics using ultra-high performance liquid chromatography and quadrupole time-of-flight mass spectrometry.
    Roy C; Tremblay PY; Bienvenu JF; Ayotte P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():40-9. PubMed ID: 27240302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of an untargeted metabolomics approach using a 2D GC-GC-MS platform to distinguish relapsing and progressive multiple sclerosis.
    Datta I; Zahoor I; Ata N; Rashid F; Cerghet M; Rattan R; Poisson LM; Giri S
    bioRxiv; 2024 Feb; ():. PubMed ID: 38370675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR-Based Metabolomics Separates the Distinct Stages of Disease in a Chronic Relapsing Model of Multiple Sclerosis.
    Dickens AM; Larkin JR; Davis BG; Griffin JL; Claridge TD; Sibson NR; Anthony DC
    J Neuroimmune Pharmacol; 2015 Sep; 10(3):435-44. PubMed ID: 26155956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica.
    Gebregiworgis T; Nielsen HH; Massilamany C; Gangaplara A; Reddy J; Illes Z; Powers R
    J Proteome Res; 2016 Feb; 15(2):659-66. PubMed ID: 26759122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis.
    Poddighe S; Murgia F; Lorefice L; Liggi S; Cocco E; Marrosu MG; Atzori L
    Int J Biochem Cell Biol; 2017 Dec; 93():148-155. PubMed ID: 28720279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
    Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
    J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of altered urinary metabolomic profiles of invasive ductal carcinoma of breast using targeted and untargeted approaches.
    More TH; Taware R; Taunk K; Chanukuppa V; Naik V; Mane A; Rapole S
    Metabolomics; 2018 Aug; 14(8):107. PubMed ID: 30830381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis.
    Gaetani L; Boscaro F; Pieraccini G; Calabresi P; Romani L; Di Filippo M; Zelante T
    Front Immunol; 2020; 11():157. PubMed ID: 32132996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease.
    Luan H; Liu LF; Meng N; Tang Z; Chua KK; Chen LL; Song JX; Mok VC; Xie LX; Li M; Cai Z
    J Proteome Res; 2015 Jan; 14(1):467-78. PubMed ID: 25271123
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 66.